FDA approves Glaxo's GLP-1

Share this article:

GlaxoSmithKline's weekly GLP-1 diabetes injection has been approved. The FDA made the announcement Tuesday morning. The type-2 diabetes drug, known in past coverage as albiglutide, is officially called Tanzeum.

The FDA was initially set to review the drug in January but said last August that it needed more time to review “information submitted by GSK in response to the [FDA's] requests.”

The approval puts GSK's new drug in a fight for patients whose choices include Novo's Victoza and AstraZeneca's Byetta/Bydureon. BMS ceded it's interest in Byetta/Bydureon last year.

Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.